Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors.
Black WC, Brideau C, Chan CC, Charleson S, Chauret N, Claveau D, Ethier D, Gordon R, Greig G, Guay J, Hughes G, Jolicoeur P, Leblanc Y, Nicoll-Griffith D, Ouimet N, Riendeau D, Visco D, Wang Z, Xu L, Prasit P. Black WC, et al. Among authors: prasit p. J Med Chem. 1999 Apr 8;42(7):1274-81. doi: 10.1021/jm980642l. J Med Chem. 1999. PMID: 10197970
The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.
Prasit P, Wang Z, Brideau C, Chan CC, Charleson S, Cromlish W, Ethier D, Evans JF, Ford-Hutchinson AW, Gauthier JY, Gordon R, Guay J, Gresser M, Kargman S, Kennedy B, Leblanc Y, Léger S, Mancini J, O'Neill GP, Ouellet M, Percival MD, Perrier H, Riendeau D, Rodger I, Zamboni R, et al. Prasit P, et al. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1773-8. doi: 10.1016/s0960-894x(99)00288-7. Bioorg Med Chem Lett. 1999. PMID: 10406640
Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O'Neill GP, Ouellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I, et al. Chan CC, et al. Among authors: prasit p. J Pharmacol Exp Ther. 1999 Aug;290(2):551-60. J Pharmacol Exp Ther. 1999. PMID: 10411562
A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitors.
Li CS, Black WC, Brideau C, Chan CC, Charleson S, Cromlish WA, Claveau D, Gauthier JY, Gordon R, Greig G, Grimm E, Guay J, Lau CK, Riendeau D, Thérien M, Visco DM, Wong E, Xu L, Prasit P. Li CS, et al. Among authors: prasit p. Bioorg Med Chem Lett. 1999 Nov 15;9(22):3181-6. doi: 10.1016/s0960-894x(99)00559-4. Bioorg Med Chem Lett. 1999. PMID: 10576684
Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx).
Nicoll-Griffith DA, Yergey JA, Trimble LA, Silva JM, Li C, Chauret N, Gauthier JY, Grimm E, Léger S, Roy P, Thérien M, Wang Z, Prasit P, Zamboni R, Young RN, Brideau C, Chan CC, Mancini J, Riendeau D. Nicoll-Griffith DA, et al. Among authors: prasit p. Bioorg Med Chem Lett. 2000 Dec 4;10(23):2683-6. doi: 10.1016/s0960-894x(00)00538-2. Bioorg Med Chem Lett. 2000. PMID: 11128651
Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.
Riendeau D, Percival MD, Brideau C, Charleson S, Dubé D, Ethier D, Falgueyret JP, Friesen RW, Gordon R, Greig G, Guay J, Mancini J, Ouellet M, Wong E, Xu L, Boyce S, Visco D, Girard Y, Prasit P, Zamboni R, Rodger IW, Gresser M, Ford-Hutchinson AW, Young RN, Chan CC. Riendeau D, et al. Among authors: prasit p. J Pharmacol Exp Ther. 2001 Feb;296(2):558-66. J Pharmacol Exp Ther. 2001. PMID: 11160644
56 results